March 18, 2013 / 11:56 AM / in 5 years

India's BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drug

MUMBAI, March 18 (Reuters) - India’s BDR Pharmaceuticals International Pvt Ltd has applied to the Indian patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co’s cancer drug, dasatinib, through a so-called compulsory licence mechanism, a BDR executive said on Monday.

Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licences for certain drugs that are deemed unaffordable to a large section of their populations.

Early this month, Bayer AG lost an appeal challenging the first-ever compulsory licence issued by India which allowed Natco Pharma to sell a version of the German drugmaker’s cancer treatment Nexavar.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below